101 related articles for article (PubMed ID: 12868352)
1. [Potential pro-thrombotic effects of cyclooxygenase-2. inhibitors Two cases pf myocardial infarction].
Thuaire C; Mankoubi L; Rangé G; Roussel L; Belfaqih H; el Khayef L; Belghit A; Charaf M; Albert F
Arch Mal Coeur Vaiss; 2003 Jun; 96(6):683-5. PubMed ID: 12868352
[TBL] [Abstract][Full Text] [Related]
2. COX-2-selective inhibitors and the risk of upper gastrointestinal bleeding in high-risk patients with previous gastrointestinal diseases: a population-based case-control study.
Nørgård B; Pedersen L; Johnsen SP; Tarone RE; McLaughlin JK; Friis S; Sørensen HT
Aliment Pharmacol Ther; 2004 Apr; 19(7):817-25. PubMed ID: 15043523
[TBL] [Abstract][Full Text] [Related]
3. [Cyclo-oxygenase 2 inhibitors and cancer].
André T; Soria JC
Bull Cancer; 2004 May; 91 Spec No():S59-60. PubMed ID: 15239332
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of aspirin in the long-term management of atherothrombosis.
Patrono C
Haematologica; 2002 Jan; 87(1):6-8. PubMed ID: 11801459
[No Abstract] [Full Text] [Related]
5. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
Chan FK; Graham DY
Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
[TBL] [Abstract][Full Text] [Related]
6. [A new class of nonsteroidal anti-inflammatory agents: COXIBs].
Costantino S
Clin Ter; 2003; 154(1):5-6. PubMed ID: 12854276
[No Abstract] [Full Text] [Related]
7. [Cardiovascular ffects of COX-2 selective anti-inflammatory agents].
Halinen MO
Duodecim; 2001; 117(24):2570-1. PubMed ID: 12183817
[No Abstract] [Full Text] [Related]
8. Utilization of nonsteroidal anti-inflammatory drugs and antisecretory agents: a managed care claims analysis.
Ofman JJ; Badamgarav E; Henning JM; Knight K; Laine L
Am J Med; 2004 Jun; 116(12):835-42. PubMed ID: 15178499
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of cyclooxygenase-2 improves cardiac function in myocardial infarction.
Saito T; Rodger IW; Hu F; Shennib H; Giaid A
Biochem Biophys Res Commun; 2000 Jul; 273(2):772-5. PubMed ID: 10873679
[TBL] [Abstract][Full Text] [Related]
10. [Cyclooxygenase 2 inhibitors and adenomatous polyposis coli].
Florent C; Meary N
Bull Cancer; 2004 May; 91 Spec No():S85-8. PubMed ID: 15239335
[TBL] [Abstract][Full Text] [Related]
11. [Safety of selective inhibitors of inducible cyclooxygenase-2 taken for a long period].
Lamarque D
Bull Cancer; 2004 May; 91 Spec No():S117-24. PubMed ID: 15239340
[TBL] [Abstract][Full Text] [Related]
12. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib.
Goldstein JL; Eisen GM; Agrawal N; Stenson WF; Kent JD; Verburg KM
Aliment Pharmacol Ther; 2004 Sep; 20(5):527-38. PubMed ID: 15339324
[TBL] [Abstract][Full Text] [Related]
13. [Safe use of anti-inflammatory analgesics].
Finnish Society of Gastroenterology and the Task force of Finnish Rheumatological Society
Duodecim; 2003; 119(22):2167-71. PubMed ID: 14702803
[No Abstract] [Full Text] [Related]
14. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
15. Aspirin and NSAID sensitivity.
Stevenson DD
Immunol Allergy Clin North Am; 2004 Aug; 24(3):491-505, vii. PubMed ID: 15242723
[TBL] [Abstract][Full Text] [Related]
16. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
Weir MR; Sperling RS; Reicin A; Gertz BJ
Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
[TBL] [Abstract][Full Text] [Related]
17. [Specific cyclo-oxygenase-2 inhibitors in cardiovascular pathology].
Monsuez JJ
Arch Mal Coeur Vaiss; 2004 Jun; 97(6):632-40. PubMed ID: 15283037
[TBL] [Abstract][Full Text] [Related]
18. A cross-sectional retrospective assessment of anti-arthritic drugs in patients with arthritis in Korea.
Lee MC; Lee S; Suh DC; Kim J; Kong SX;
Curr Med Res Opin; 2003; 19(7):597-602. PubMed ID: 14606981
[TBL] [Abstract][Full Text] [Related]
19. Cyclooxygenase-2 specific inhibitors in the treatment of dysmenorrhea.
Harel Z
J Pediatr Adolesc Gynecol; 2004 Apr; 17(2):75-9. PubMed ID: 15050982
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
van der Bijl P; van der Bijl P
Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
